John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.
As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the Melanoma Center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to properly monitor responses in patients with metastatic melanoma.
In the video series, Kirkwood discussed the following:
To watch more videos from the CancerNetwork® OncView™ series, visit cancernetwork.com/oncview.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Tebentafusp Continues to Demonstrate Benefit in Metastatic Uveal Melanoma
January 4th 2024Results from a long-term analysis of the phase 3 IMCgp100-202 trial indicate that tebentafusp results in better disease control and long-lasting responses in those with HLA-A*02:01–positive, previously untreated metastatic uveal melanoma.